Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin D

Cancer Research

Volumn 66, Issue 6, 2006, Pages 3177-3187

  Kluza, Jérôme ^a   Gallego, Miguel Angel ^a   Loyens, Anne ^a   Beauvillain, Jean Claude ^a   Sousa Faro, José Maria Fernandez ^b   Cuevas, Carmen ^b   Marchetti, Philippe ^a   Bailly, Christian ^a,c  

^a INSERM   (France)

^b PHARMAMAR S A   (Spain)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CAMPTOTHECIN; CASPASE INHIBITOR; CYCLOSPORIN A; CYTOCHROME C; DNA TOPOISOMERASE INHIBITOR; LAMELLARIN D; PM 031379; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL FREE SYSTEM; CELL STRAIN 3T3; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA CLEAVAGE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; LEUKEMIA P 388; MEMBRANE PERMEABILITY; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSMISSION ELECTRON MICROSCOPY;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CELL-FREE SYSTEM; COUMARINS; CYTOCHROMES C; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; ISOQUINOLINES; LEUKEMIA P388; LUNG NEOPLASMS; MEMBRANE POTENTIALS; MICE; MITOCHONDRIA; MITOCHONDRIAL MEMBRANES; NIH 3T3 CELLS; RATS;

EID: 33645527573     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1929     Document Type: Article

References (37)

1. Andersen RJ, Faulkner DJ, Cun-heng H, Van Duyne GD, Clardy J. Metabolites of the marine prosobranch mollusk Lamellaria sp. J Am Chem Soc 1985;107:5492-5.
2. Bailly C. Lamellarins, from A to Z: a family of anticancer marine pyrrole alkaloids. Curr Med Chem Anti-Canc Agents 2004;4:363-78.
3. Quesada AR, Barbacid MM, Mira E, Aracil M, Marquez G. Chemosensitization and drug accumulation assays as complementary methods for the screening of multidrug resistance reversal agents. Cancer Lett 1996;99:109-14.
4. Facompré M, Tardy C, Bal-Mahieu C, et al. Lamellarin D: a novel potent inhibitor of topoisomerase I. Cancer Res 2003;63:7392-9.
5. Tardy C, Facompre M, Laine W, et al. Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues. Bioorg Med Chem 2004;12:1697-712.
6. Marco E, Laine W, Tardy C, et al. Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with camptothecin and structure-activity relationships. J Med Chem 2005;48:3796-807.
7. Luber-Narod J, Sousa-Faro J, Cuevas C, Aviles P, Faircloth G. In vitro toxicology studies of lamellarins M, D, and K and 4 synthetic analogs [poster 639]. Am Assoc Cancer Res 2005.
8. Elices M, Grant W, Luber-Narod J, et al. Lamellarins, novel marine compounds showing efficacy in a panel of human tumor xenografts [poster 645]. Am Assoc Cancer Res 2005.
9. Vanhuyse M, Kluza J, Tardy C, et al. Lamellarin D: a novel pro-apoptotic agent from marine origin insensitive to P-glycoprotein-mediated drug efflux. Cancer Lett 2005;221:165-75.
10. Costantini P, Jacotot E, Decaudin D, Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 2000;92:1042-53.
11. Dias N, Bailly C. Drugs targeting mitochondrial function to control tumor cell growth. Biochem Pharmacol 2005;70:1-12.
12. Marchetti P, Mortier L, Beauvillain V, Formstecher P. Are mitochondria targets of anticancer drugs responsible for apoptosis? Ann Biol Clin (Paris) 2002;60:391-403.
13. Debatin KM, Poncet D, Kroemer G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 2002;21:8786-803.
14. Madeleine I, Prost S, Naudin A, Riou G, Lavelle F, Riou JF. Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation. Biochem Pharmacol 1993;45:339-48.
15. Kluza J, Marchetti P, Gallego MA, et al. Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene 2004;23:7018-30.
16. Gallego MA, Joseph B, Hemstrom TH, et al. Apoptosis-inducing factor determines the chemoresistance of non-small-cell lung carcinomas. Oncogene 2004;23:6282-91.
17. Lecoeur H, Langonne A, Baux L, et al. Real-time flow cytometry analysis of permeability transition in isolated mitochondria. Exp Cell Res 2004;294:106-17.
18. Bailly C. DNA relaxation and cleavage assays to study topoisomerase I inhibitors. Methods Enzymol 2001;340: 610-23.
19. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta 1995;1241:139-76.
20. Zamzami N, Kroemer G. The mitochondrion in apoptosis: how Pandora's box opens. Nat Rev Mol Cell Biol 2001;2:67-71.
21. Zamzami N, Susin SA, Marchetti P, et al. Mitochondrial control of nuclear apoptosis. J Exp Med 1996;183: 1533-44.
22. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004;305:626-9.
23. Marchetti P, Zamzami N, Joseph B, et al. The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. Cancer Res 1999;59:6257-66.
24. Nagle DG, Zhou YD, Mora FD, Mohammed KA, Kim YP. Mechanism targeted discovery of antitumor marine natural products. Curr Med Chem 2004;11:1725-56.
25. Grad JM, Cepero E, Boise LH. Mitochondria as targets for established and novel anti-cancer agents. Drug Resist Updat 2001;4:85-91.
26. Don AS, Hogg PJ. Mitochondria as cancer drug targets. Trends Mol Med 2004;10:372-8.
27. Szewczyk A, Wojtczak L. Mitochondria as a pharmacological target. Pharmacol Rev 2002;54:101-27.
28. Chen LB. Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 1988;4:155-81.
29. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999;24:68-72.
30. Fantin VR, Leder P. F16, a mitochondriotoxic compound, triggers apoptosis or necrosis depending on the genetic background of the target carcinoma cell. Cancer Res 2004;64:329-36.
31. Fantin VR, Berardi MJ, Scorrano L, Korsmeyer SJ, Leder P. A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer Cell 2002;2:29-42.
32. 1-ATpase. Chem Biol 2001;8:71-80.
33. Rotem R, Heyfets A, Fingrut O, Blickstein D, Shaklai M, Flescher E. Jasmonates: novel anticancer agents acting directly and selectively on human cancer cell mitochondria. Cancer Res 2005;65:1984-93.
34. Flescher E. Jasmonates-a new family of anti-cancer agents. Anticancer Drugs 2005;16:911-6.
35. Bernal SD, Lampidis TJ, Summerhayes IC, Chen LB. Rhodamine-123 selectively reduces clonal growth of carcinoma cells in vitro. Science 1982;218:1117-9.
36. Nadakavukaren KK, Nadakavukaren JJ, Chen LB. Increased rhodamine 123 uptake by carcinoma cells. Cancer Res 1985;12:6093-9.
37. Belzacq AS, El Hamel C, Vieira HL, et al. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite, and CD437. Oncogene 2001;20: 7579-87.